title: Treatment of metastatic melanoma with pazopanib: A report of five patient cases.
abstract: Metastatic melanoma has a median length of survival after diagnosis of 6-9 months. Unfortunately, the National Comprehensive Cancer Network clinical practice guidelines for treating stage IV, unresectable, metastatic melanoma are limited with regard to treatment options. Pazopanib (Votrient™) is FDA-approved for advanced soft tissue sarcoma and advanced renal cell carcinoma. Limited research exists for using pazopanib in the treatment of metastatic melanoma. We present five cases in which pazopanib was used in combination with paclitaxel ± carboplatin for treatment of unresectable, metastatic melanoma.
authors.affiliation: Department of Pharmacy Practice, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA ledayer@uams.edu.
authors.forename: Lindsey E
authors.initials: LE
authors.lastname: Dayer
authors.affiliation: Department of Internal Medicine, Division of Hematology and Oncology, University of Arkansas for Medical Sciences College of Medicine, Little Rock, AR, USA.
authors.forename: Laura F
authors.initials: LF
authors.lastname: Hutchins
authors.affiliation: Department of Pharmacy Practice, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA.
authors.forename: Jill T
authors.initials: JT
authors.lastname: Johnson
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007191:Indazoles; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D011743:Pyrimidines / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib; D016190:Carboplatin
keywords: Votrient; metastatic melanoma; pazopanib